二、前10名无限售条件股东持股情况 前十大流通股东累计持有： 30038.1万股，累计占流通股比： 74.85%，较上期变化： 50.80万 股。 | 名称 持有数量(万股) | | 占总股本比例(%) | 增减情况(万股) | | --- | --- | --- | --- | | 易瑞(海南)创业投资有限公司 | 13590.12 | 33.86 | 不变 | | 朱海 | 6769.25 | 16.87 | 不变 | | 王天一 | 2640.35 | 6.58 | 不变 | | 深圳易凯瑞管理咨询合伙企业(有限合伙) | 2315.29 | 5.77 | 不变 | | 深圳易达瑞管理咨询合伙企业(有限合伙) | 1941.92 | 4.84 | 不变 | | 卢和华 | 969.79 | 2.42 | 不变 | | 付辉 | 911.70 | 2.27 | 不变 | | 林季敏 | 530.30 | 1.32 | -50.00 | | 吴志丹 | 201.34 | 0.50 | 新进 | | 刘小平 | 168.04 | 0.42 | 新进 | | 较上个报告期退出前十大股东有 | | | | | U ...

| 证券代码：300942 | 证券简称：易瑞生物 公告编号：2025-019 | | --- | --- | | 债券代码：123220 | 债券简称：易瑞转债 | 深圳市易瑞生物技术股份有限公司 关于召开公司 2024 年度股东大会的通知 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 深圳市易瑞生物技术股份有限公司（以下简称"公司"）于2025年4月24日 召开第三届董事会第十次会议，公司董事会决定于2025年5月16日（星期五）14:30 以现场表决与网络投票相结合的方式召开2024年度股东大会（以下简称"本次会 议"或"本次股东大会"）。现将本次会议的相关事项通知如下： 一、召开会议的基本情况 1、股东大会届次：2024 年度股东大会 2、股东大会的召集人：公司董事会 3、会议召开的合法、合规性： 公司于 2025 年 4 月 24 日召开第三届董事会第十次会议，审议通过了《关于 召开公司 2024 年度股东大会的议案》。本次股东大会的召集程序符合有关法律、 行政法规、部门规章、规范性文件和《公司章程》等有关规定。 4、会议召开的时间： （1）现场会 ...

| 证券代码：300942 | 证券简称：易瑞生物 公告编号：2025-010 | | --- | --- | | 债券代码：123220 | 债券简称：易瑞转债 | 深圳市易瑞生物技术股份有限公司 第三届监事会第五次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 深圳市易瑞生物技术股份有限公司（以下简称"公司"）于2025年4月24日 （星期四）在深圳市宝安区航城街道三围社区运昌路289号易瑞生物产业园会议 室以现场表决的方式召开了第三届监事会第五次会议。本次会议通知已于2025 年4月14日以电子邮件、微信等方式送达全体监事。 本次会议由监事会主席莫秋华先生召集并主持，本次会议应出席监事3人， 实际出席监事3人；公司董事会秘书列席了本次会议。本次会议的召集、通知、 召开和表决程序均符合《公司法》等有关法律、行政法规、规范性文件、部门规 章及《公司章程》的有关规定，会议合法、有效。 二、监事会会议审议情况 经与会监事审议并以书面记名投票的方式对本次会议的议案进行了表决，审 议结果如下： 1、审议通过《关于公司 2024 ...

| 证券代码：300942 | 证券简称：易瑞生物 | 公告编号：2025-009 | | --- | --- | --- | | 债券代码：123220 | 债券简称：易瑞转债 | | 深圳市易瑞生物技术股份有限公司 第三届董事会第十次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 深圳市易瑞生物技术股份有限公司（以下简称"公司"）于2025年4月24日 （星期四）在深圳市宝安区航城街道三围社区运昌路289号易瑞生物产业园公司 会议室以现场与通讯表决相结合的方式召开了第三届董事会第十次会议。本次会 议通知已于2025年4月14日以电子邮件、微信等方式送达全体董事。 本次会议由董事长肖昭理先生召集并主持，本次会议应出席董事7人，实际 出席董事7人（现场出席董事3人，通讯出席董事4人），公司全体监事、高级管 理人员列席了本次会议。本次会议的召集、通知、召开和表决程序均符合《公司 法》等有关法律、行政法规、规范性文件、部门规章及《公司章程》的有关规定， 会议合法、有效。 二、董事会会议审议情况 经与会董事审议并以书面记名投票的 ...

| 证券代码：300942 | 证券简称：易瑞生物 公告编号：2025-014 | | --- | --- | | 债券代码：123220 | 债券简称：易瑞转债 | 深圳市易瑞生物技术股份有限公司 关于 2024 年度利润分配预案的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、审议程序 深圳市易瑞生物技术股份有限公司（以下简称"公司"）于 2025 年 4 月 24 日召开第三届董事会第十次会议和第三届监事会第五次会议，分别全票审议通过 了《关于公司 2024 年度利润分配预案的议案》，该议案尚需提交公司 2024 年度 股东大会审议。 | 项目 | 2024 年度 | 2023 年度 | 2022 年度 | | --- | --- | --- | --- | | 现金分红总额（元） | 6,998,962.67 | 0 | 8,498,232.00 | | 回购注销总额（元） | 0 | 0 | 0 | | 归属于上市公司股东的 | 17,116,524.08 | -184,907,769.73 | 82,965,490.95 | 1 | 净利 ...

Revenue and Profitability - The company's revenue for Q1 2025 was ¥49,342,908.97, representing a 35.28% increase compared to ¥36,475,073.45 in the same period last year[5] - Net profit for the current period was -¥4,233,747.89, an improvement from -¥7,273,762.66 in the previous period, indicating a reduction in losses[19] - Basic and diluted earnings per share improved to -¥0.0083, a 53.11% increase from -¥0.0177 in the previous year[5] - Basic and diluted earnings per share improved to -¥0.0083 from -¥0.0177 in the previous period[20] Cash Flow - The net cash flow from operating activities was negative at ¥1,415,234.47, a decline of 115.04% compared to a positive cash flow of ¥9,412,805.78 in the same period last year[5] - The company reported a net cash inflow from operating activities of ¥67,267,138.19, compared to ¥65,457,841.42 in the previous period[22] - The net cash flow from investing activities was positive at 160,720,396.32, a substantial improvement from a negative cash flow of -35,652,211.67 in the prior period, reflecting successful investment recovery efforts[23] - The net cash flow from financing activities was positive at 656,140.77, down from 46,120,022.70 in the previous period, suggesting a decrease in financing activities[23] - The cash outflow from operating activities totaled 68,682,372.66, compared to 56,045,035.64 in the previous period, showing an increase in operational cash expenses[23] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,443,075,606.54, a decrease of 0.97% from ¥1,457,165,935.92 at the end of the previous year[5] - The company's total current assets amount to 730,932,473.54 RMB, a decrease from 751,616,151.89 RMB at the beginning of the period[15] - The total liabilities decreased slightly to ¥576,727,249.39 from ¥586,923,364.94, a decline of 1.7%[16] - The total liabilities include accounts payable of 51,219,299.39 RMB, down from 58,762,442.61 RMB[15] - The company reported a decrease in contract liabilities to 19,356,363.94 RMB from 24,992,820.15 RMB[15] Shareholder Information - The total number of common shareholders at the end of the reporting period is 18,731[11] - The largest shareholder, Yirui (Hainan) Venture Capital Co., Ltd., holds 33.86% of shares, totaling 135,901,179 shares, with 80,000,000 shares pledged[11] - The second-largest shareholder, Zhu Hai, owns 16.87% of shares, amounting to 67,692,519 shares, with 16,850,000 shares pledged[11] Operating Costs and Expenses - The operating costs surged by 153.85% to ¥23,502,052.28, primarily due to increased revenue and a higher proportion of equipment-related products[9] - Total operating costs increased to ¥55,561,251.36, up 25.2% from ¥44,390,455.72 in the previous period[18] - Research and development expenses decreased to ¥8,238,945.94 from ¥10,280,504.62, reflecting a 19.8% reduction[19] - The cash paid to employees increased to 27,403,778.22 from 26,272,515.25, indicating a rise in payroll expenses[23] Investment Performance - The company recorded a 912.75% increase in fair value changes, amounting to ¥903,784.58, attributed to the fair value changes of financial products[9] - The company’s investment income received cash increased by 842.57% to ¥1,762,483.79, reflecting higher returns from financial investments[9] - The company recorded a net investment loss of -¥2,089,627.24, worsening from -¥1,663,633.85 in the previous period[19] - The cash inflow from investment activities totaled 219,005,301.56, significantly higher than 30,357,118.70 in the previous period, indicating strong investment performance[23] Tax and Other Income - The company experienced a 100% decrease in cash received from tax refunds, dropping to ¥0.00 from ¥7,225,626.82, due to reduced export tax refunds[9] - The cash paid for taxes increased to 1,248,847.70 from 681,690.26, reflecting higher tax obligations[23] - Other comprehensive income after tax was -¥209,889.51, compared to -¥66,277.39 in the previous period, indicating a larger loss in this category[20] Cash and Cash Equivalents - The company reported a significant increase in cash and cash equivalents, rising by 42.89% to ¥419,229,213.25 due to the redemption of financial products[9] - Cash and cash equivalents increased to 419,229,213.25 RMB from 293,399,311.14 RMB, reflecting a growth of approximately 42.9%[14] - The total cash and cash equivalents at the end of the period amounted to 418,886,074.71, a decrease from 500,350,687.09 at the end of the previous period[23] - The impact of exchange rate changes on cash and cash equivalents was positive at 1,792,812.67, contrasting with a negative impact of -1,278,804.52 in the previous period[23]

Financial Performance - The company's operating revenue for 2024 was ¥224,249,109.55, a decrease of 11.75% compared to ¥254,106,487.66 in 2023[17]. - The net profit attributable to shareholders for 2024 was ¥17,116,524.08, representing a significant increase of 109.26% from a loss of ¥184,907,769.73 in 2023[17]. - The cash flow from operating activities for 2024 was ¥34,258,202.60, a remarkable improvement of 191.97% compared to -¥37,249,852.89 in 2023[17]. - The total assets at the end of 2024 amounted to ¥1,457,165,935.92, reflecting a growth of 7.43% from ¥1,356,339,278.93 at the end of 2023[17]. - The basic earnings per share for 2024 was ¥0.04, a turnaround from -¥0.46 in 2023, marking an increase of 108.70%[17]. - The company reported a weighted average return on equity of 1.99% for 2024, a significant recovery from -21.22% in 2023[17]. - The company’s net profit after deducting non-recurring gains and losses for 2024 was -¥1,778,814.32, an improvement of 99.08% from -¥193,906,931.05 in 2023[17]. - The company’s revenue after deducting certain amounts was ¥215,901,036.72 in 2024, compared to ¥248,939,445.80 in 2023[17]. - The company’s total net assets attributable to shareholders at the end of 2024 were ¥869,005,338.22, a slight increase of 2.36% from ¥848,993,883.06 at the end of 2023[17]. - The company’s quarterly revenue for Q4 2024 was ¥66,201,216.30, contributing to a total annual revenue of ¥224,249,109.55[19]. Dividend Distribution - The company plans to distribute a cash dividend of 0.1744 RMB per 10 shares to all shareholders, based on a total of 401,316,667 shares[3]. - The company has no plans for cash dividends, stock bonuses, or capital reserve transfers for the 2023 fiscal year[188]. Market and Industry Trends - The global food safety testing market is projected to reach $33.7 billion by 2028, with a compound annual growth rate (CAGR) of 8.2%[28]. - In China, the government has implemented a series of policies to enhance food safety, including the revised Food Safety Law, which supports rapid testing technologies[29]. - The 2021 "14th Five-Year" market supervision modernization plan emphasizes improving food safety testing capabilities and establishing a comprehensive food safety responsibility system[30]. - The new national standard for food additives (GB 2760-2024) imposes stricter regulations on the use of food additives, ensuring higher safety standards in food production[30]. - The rapid testing market is expected to grow significantly due to increasing government demand for food safety risk monitoring and testing[31]. - The implementation of the revised Agricultural Product Quality Safety Law enhances pre-market testing and strengthens regulatory oversight of agricultural products[30]. - The food safety testing market in China is driven by the need to address issues such as pesticide and veterinary drug residues, as well as food adulteration[29]. - The government is focusing on enhancing food safety in schools and promoting a comprehensive safety system from procurement to dining[30]. - The rapid testing technology is becoming increasingly integrated, automated, and focused on risk monitoring, improving the efficiency of food safety inspections[28]. - The market for rapid testing products is expected to expand as domestic testing technologies mature and standards are established[31]. Product Development and Innovation - The company has a focus on developing new products and technologies, although specific details are not provided in the current report[3]. - The company has developed a comprehensive food safety testing system covering various stages from feed to retail, ensuring food safety throughout the supply chain[35]. - The company’s rapid testing products include a high-throughput pesticide residue detection card capable of testing 16 pesticide residues simultaneously within 9 minutes[37]. - The animal diagnostics business includes a series of rapid pregnancy detection products for cattle and sheep, significantly enhancing farm economic efficiency[40]. - The company’s animal diagnostics products have received GMP certification and cover both economic and companion animals, with over 30 detection products for common pet diseases[39]. - The company’s food safety rapid testing instruments enable real-time data sharing and analysis, enhancing food safety monitoring capabilities[38]. - The company has established a "self-research and technology cooperation" model for product development, focusing on market-driven needs and combining government projects with industry-academia collaboration[41]. - The company has launched four microbial test products that significantly reduce testing time to approximately 18-24 hours, compared to the traditional 3-5 days[49]. - The company has developed a high-throughput pesticide residue rapid detection card that can simultaneously detect 16 types of pesticide residues within 9 minutes, significantly outperforming traditional enzyme inhibition methods[50]. - The company has improved the sample pre-treatment process, reducing it from a traditional five-step method to a two-step method, significantly shortening detection time[67]. Research and Development - The company has invested heavily in R&D, focusing on antigen-antibody self-manufacturing and efficient pre-treatment technologies, leading to a competitive edge in product quality and cost reduction[64]. - The total amount of research and development investment was ¥40,452,354.02, accounting for 18.04% of operating revenue[97]. - Research and development expenses decreased by 23.88% to ¥40,452,354.02, primarily due to the contraction of the in vitro diagnostic business[96]. - The company has obtained 11 new domestic invention patents, including a rapid detection method for penicillin in fruit and vegetable juices[83]. Governance and Management - The company has established a governance structure in compliance with relevant laws and regulations, ensuring the protection of shareholder rights, particularly for minority shareholders[144]. - The board of directors consists of 7 members, including 3 independent directors, ensuring a diverse range of expertise and compliance with legal requirements[146]. - The company maintains independence from its controlling shareholders, with no interference in decision-making or operational activities[145]. - The company has a complete and independent business operation, with no competition or unfair transactions with controlling shareholders[152]. - The company has established a robust information disclosure system, ensuring timely and accurate communication with investors[149]. - The company has a dedicated financial department with an independent accounting system, ensuring financial autonomy[156]. - The company has a structured approach to remuneration that aligns with its operational status and legal regulations[170]. - The company has established a market value management system and is in the process of implementing a valuation enhancement plan[142]. - The company is committed to transparency, as shown by its detailed records of investor interactions available on the official website[139]. Employee Relations and Corporate Culture - The company has established a comprehensive training plan to enhance employee skills and core competitiveness[187]. - The company has a structured approach to employee recognition, including annual awards to enhance morale and corporate culture[186]. - The total number of employees at the end of the reporting period is 480, with 265 in the parent company and 215 in major subsidiaries[184]. - The company has a diverse professional composition, with 200 technical personnel, 107 sales personnel, and 99 production personnel[185]. - The company emphasizes a performance-oriented compensation policy, aiming to attract and retain talent with competitive salary packages[186]. Risk Management - The company emphasizes the importance of risk awareness regarding future plans and development strategies, as outlined in the management discussion section[3]. - The company has outlined potential risks and corresponding mitigation strategies in its future outlook section[3]. - The company acknowledges the risk of policy changes affecting the food safety testing industry and is focused on adapting to regulatory dynamics[135]. - R&D innovation risks are recognized, with a commitment to enhancing technological advancement and product quality to maintain competitiveness[136]. - The company emphasizes cost control and operational efficiency to mitigate the risk of declining gross margins in its main business[138]. Investor Relations - The company is actively expanding its investor relations activities, as evidenced by multiple scheduled communications throughout 2024[140]. - The company is focusing on enhancing its business conditions through regular updates and engagements with investors[141]. - The company plans to enhance its collaboration with large dairy enterprises and food production companies to increase its market share and develop new leading enterprise clients[54]. - The company has established several subsidiaries during the reporting period, including Inner Mongolia Yirui Biotechnology Co., Ltd., with no significant impact on overall operations[128]. Strategic Initiatives - The company is committed to advancing smart detection products to improve efficiency and compliance in food safety testing[133]. - A platform-based strategy will be implemented to integrate resources and meet diverse detection needs across various scenarios[134]. - The company is undergoing strategic adjustments, which led to the resignation of Deputy General Manager Gao Shitao on July 4, 2024[162]. - The company has appointed Jinlong Zhang as the new Deputy General Manager on July 4, 2024, as part of the strategic realignment[162].

| 证券代码：300942 | 证券简称：易瑞生物 | 公告编号：2025-008 | | --- | --- | --- | | 债券代码：123220 | 债券简称：易瑞转债 | | 深圳市易瑞生物技术股份有限公司 关于控股股东部分股份解除质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 深圳市易瑞生物技术股份有限公司（以下简称"公司"）近日收到控股股东 易瑞（海南）创业投资有限公司（以下简称"易瑞创投"）的通知，获悉其所持 有公司的部分股份办理了解除质押业务，具体事项如下： | 股东名称 | 是否为控股股东 或第一大股东及 | 本次解除质 押股份数量 | 占其所持 | 占公司 总股本 | 质押起始日 | 解除质押 | 质权人 | | --- | --- | --- | --- | --- | --- | --- | --- | | | | | 股份比例 | | | 日 | | | | 其一致行动人 | （股） | | 比例 | | | | | 易瑞（海南）创 | | | | | 2024 年 4 | 2025 年 4 | 深圳担保 | | 业投 ...

| 证券代码：300942 | 证券简称：易瑞生物 公告编号：2025-007 | | --- | --- | | 债券代码：123220 | 债券简称：易瑞转债 | 深圳市易瑞生物技术股份有限公司 关于控股股东部分股份解除质押及再质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚 假记载、误导性陈述或重大遗漏。 二、股东股份质押的基本情况 1、本次股份质押基本情况 | 股东名称 | 是否为控股 股东或第一 | 本次质押 | 占其所 | 占公司 | 是否 | 是否为 | 质押起始 | 质押到 | | 质押 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 大股东及其 | 数量 | 持股份 | 总股本 | 为限 | 补充质 | 日 | 期日 | 质权人 | 用途 | | | 一致行动人 | （股） | 比例 | 比例 | 售股 | 押 | | | | | | | | | | | | | | | 深圳市 | | | 易瑞（海 | | | | | | | | 办理解 | | | | | | ...

作 者丨 易妍君 编 辑丨包芳鸣 黎雨桐 4月9日，A股港股、亚太股市集体低开。 截至发稿，上证指数跌超2%，深证成指跌超3%，创业板指跌超3%。 | 上证指数 | 深证成指 | 北证50 | | --- | --- | --- | | 3075.75 | 9138.12 | 1069.49 | | -69.80 -2.22% -286.56 -3.04% -24.90 -2.28% | | | | 科创50 | 创业板指 | 万得全A | | 920.49 | 1782.94 | 4514.46 | | -19.60 -2.09% -57.37 -3.12% | | -160.08 -3.42% | | 沪深300 | 中证500 | 中证A500 | | 3594.22 | 5141.90 | 4170.06 | | -56.54 -1.55% -185.02 -3.47% -89.25 -2.10% | | | | 中证1000 | 中证2000 | 中证红利 | | 5232.41 | 2027.20 | 5144.99 | | -297.60 -5.38% -155.92 -7.14% | | -1 ...